10x Genomics EBITDA margin
¿Qué es el EBITDA margin de 10x Genomics?
El EBITDA margin de 10x Genomics, Inc. es -18.54%
¿Cuál es la definición de EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin de compañías en Sector Health Care en NASDAQ en comparadas con 10x Genomics
¿Qué hace 10x Genomics?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Empresas con ebitda margin similar a 10x Genomics
- Conversion Labs tiene EBITDA margin de -18.74%
- Central Petroleum tiene EBITDA margin de -18.72%
- KK Culture tiene EBITDA margin de -18.63%
- Tortoise Power and Infrastructure Fund tiene EBITDA margin de -18.63%
- Sintex Plastics Technology tiene EBITDA margin de -18.61%
- Malachite Resources tiene EBITDA margin de -18.58%
- 10x Genomics tiene EBITDA margin de -18.54%
- Northeast Electric Development tiene EBITDA margin de -18.54%
- Horizon Discovery plc tiene EBITDA margin de -18.54%
- Lake Resources N.L tiene EBITDA margin de -18.53%
- Farfetch Ltd tiene EBITDA margin de -18.53%
- Lannett Co tiene EBITDA margin de -18.41%
- Parazero tiene EBITDA margin de -18.39%